Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis

详细信息    查看全文

• 作者：Nathan T. Connell^a ; ^c ; ^{NTConnell@partners.org} ; Gregory A. Abel^b ; ^c ; Jean M. Connors^a ; ^c
• 刊名：Thrombosis Research
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：150
• 期：Complete
• 页码：53-58
• 全文大小：482 K
• 卷排序：150

文摘

Cost-effectiveness of anticoagulation for cancer-associated thrombosis is performed. Markov modeling is used to derive quality-adjusted life years and costs. Low-molecular weight heparin provided an additional 14 weeks. Cost was $217,007 per additional quality-adjusted life year gained. Low-molecular weight heparin is not cost-effective at standard thresholds.